The company behind the molecule, the original two-vial product, and the concentrated formulation approved in 2018

Published 26 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
Theratechnologies, a Montreal biotechnology company, licensed the growth hormone-releasing hormone analogue programme in the 1990s, selected the hexenoyl analogue, and took it through development to the 2010 approval. The original product was a lyophilised powder with mannitol as a bulking agent, supplied in vials for reconstitution. In 2018 the United States regulator approved a reformulated product at higher concentration that halved the number of vials and injections, and the company later developed a further formulation intended to be stored at room temperature. Each change required stability and comparability data showing the peptide unchanged.

The company

A small company that built itself around one molecule, with the HIV lipodystrophy indication as its route to market. It has since added an HIV antibody to its portfolio and has pursued tesamorelin for liver fat in HIV, with the Stanley trials as the main evidence. It remains the owner of the molecule and its patents.

The development history is a common one for a specialty peptide.

Why formulation matters

A 44-residue peptide with a methionine, an asparagine prone to deamidation and a hydrophobic acyl group is chemically fragile in solution, which is why the approved product is lyophilised and reconstituted. Mannitol provides the cake structure and tonicity. Increasing concentration changes aggregation and dissolution behaviour and requires new stability data. A room-temperature formulation requires solving the degradation routes the pages on this site describe.

The research-grade product in this catalogue is a lyophilised powder with its own batch documentation and is not any of these approved formulations.

Why it is here

Because the formulation history shows what is involved in keeping this molecule stable, and because a reader should know who owns it. It describes history and no use of the pack.

Tesamorelin is supplied by REVIVE LAB UAE for laboratory research use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
Tesamorelin Pack20 mgAED 1010In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

The company?

A small company that built itself around one molecule, with the HIV lipodystrophy indication as its route to market. It has since added an HIV antibody to its portfolio and has pursued tesamorelin for liver fat in HIV, with the Stanley trials as the main evidence. It remains the owner of the molecule and its patents.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

Tesamorelin Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.